Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic

Journal of Thrombosis and Thrombolysis

Volumn 30, Issue 2, 2010, Pages 220-225

  Shaw, Paul B ^a   Donovan, Jennifer L ^b   Tran, Maichi T ^c   Lemon, Stephenie C ^d   Burgwinkle, Pamela ^c   Gore, Joel ^c  

^a Kaiser Permanente of Colorado   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c UMASS MEMORIAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Genotype; Pharmacogenetics; Pharmacogenomics; Warfarin

Indexed keywords

COUMARIN; CYTOCHROME P450 2C9; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

ACCURACY; ADULT; ALGORITHM; ANTICOAGULATION; ARTICLE; DRUG DOSE REGIMEN; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL; AGED; BLOOD CLOTTING; COMPARATIVE STUDY; DOSE CALCULATION; DRUG EFFECTS; DRUG MONITORING; EVALUATION STUDY; GENETIC SCREENING; GENETICS; INTERNATIONAL NORMALIZED RATIO; METABOLISM; MIDDLE AGED; OUTPATIENT DEPARTMENT; PHENOTYPE; REPRODUCIBILITY; UNITED STATES;

ACADEMIC MEDICAL CENTERS; AGED; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; GENETIC TESTING; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MASSACHUSETTS; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OUTPATIENT CLINICS, HOSPITAL; PHARMACOGENETICS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; WARFARIN; CYTOCHROME P-450 CYP2C9; VITAMIN K EPOXIDE REDUCTASES;

EID: 77957963225     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0459-3     Document Type: Article

References (16)

1. Lamb E (May 2009) Top 200 drugs of 2008. Pharmacy Times web site. www.pharmacytimes.com/issue/pharmacy/2009/2009-05/RxFocusTop200Drugs-0509. Accessed June 14, 2009
2. Gage BF, Eby C, Johnson JA et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. J Clin Ther 84:326-331
3. Kaminsky LS, Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74
4. Higashi MK, Veenstra DL, Kondo LM et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690-1698
5. Reider MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293
6. Bristol-Myers Squibb Company. COUMADIN [warfarin] package insert. Princeton, NJ; August 2007
7. Gage BF, Eby C, Milligan PE et al (2004) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91:87-94
8. Sconce EA, Khan TI, Wynn HA et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics on warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329-2333
9. Zhu Y, Shennan M, Reynolds KK et al (2007) Estimation of warfarin maintenance dose based on VKORC1 (-1639G>A) and CYP2C9 genotypes. Clin Chem 53:1199-1205
10. Wadelius M, Chen LY, Lindh JD et al (2008) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784-792
11. International Warfarin Pharmacogenetics Consortium (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753-764
12. Voora D, Eby C, Linder MW et al (2005) Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 93:700-705
13. Kangelaris KN, Bent S, Nussbaum RL et al (2009) Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 24:656-664
14. Eckman MH, Rosand J, Greenberg SM et al (2009) Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 150:73-83
15. Anderson JL, Horne BD, Stevens SM et al (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116:2563-2570
16. Lindh JD, Lungren S, Holm L et al (2005) Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 78:540-550